Grail Catapults 30%-Plus As FDA Mulls Cancer-Detecting Blood Test — Live Feedhttps://www.live-feeds.com/feed/grail-catapults-30-plus-as-fda-mulls-cancer-detecting-blood-testContinuously updated, source-cited coverage. Grail Shares Surge as FDA Staff Report No Major Concerns for Galleri Testhttps://www.live-feeds.com/feed/grail-catapults-30-plus-as-fda-mulls-cancer-detecting-blood-testhttps://www.live-feeds.com/feed/grail-catapults-30-plus-as-fda-mulls-cancer-detecting-blood-test#u81747Wed, 23 Sep 2026 20:20:24 +0000Grail stock rose more than 30% following the release of FDA briefing documents that showed a positive evaluation of its Galleri multi-cancer blood test. FDA staff indicated they have no major concerns regarding the test, which is designed to detect cancer in healthy individuals. This rally marks the company's best trading day in over 1.5 years. The positive internal review comes just as the FDA prepares for an advisory committee meeting to evaluate the test's efficacy and regulatory approval path.Why it mattersThe Galleri test aims to identify multiple types of cancer through a singl